Federal Food & Drug AdministrationNeuproParkinson's diseaseAnnouncement

FDA approval

9 May, 2007

The FDA announces the approval of Neupro, the first skin patch designed to treat symptoms of early Parkinson’s disease.¬†Neupro patches, which are changed daily, deliver rotigotine through the skin. Rotigotine is a member of a class of drugs called dopamine agonists, which mimic dopamine’s effects.

Add your comments below...